Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878573 | 0.94 | HTR6 (0.51) | HTR6CXCR4CYP2D6SLC40A1KCNH2 | |
| SCHEMBL4889721 | 0.94 | HTR6 (0.50) | HTR6CXCR4CYP2D6SLC40A1KCNH2 | |
| SCHEMBL14270231 | 0.85 | CXCR4 (0.42) | CXCR4CYP2D6SLC40A1OPRL1KCNH2 | |
| SCHEMBL27889942 | 0.82 | HDAC1 (0.46) | CXCR4KCNH2 | |
| SCHEMBL4881639 | 0.81 | CXCR4 (0.52) | HTR6CXCR4KCNH2 | |
| SCHEMBL14270246 | 0.79 | CXCR4 (0.44) | CXCR4CYP2D6SLC40A1KCNH2 | |
| SCHEMBL4166431 | 0.79 | CXCR4 (0.60) | HTR6CXCR4CYP2D6KCNH2DRD4 | |
| SCHEMBL4170853 | 0.79 | CXCR4 (0.60) | HTR6CXCR4CYP2D6KCNH2DRD4 | |
| SCHEMBL5548249 | 0.79 | CXCR4 (0.60) | HTR6CXCR4CYP2D6KCNH2DRD4 | |
| SCHEMBL13875216 | 0.79 | CXCR4 (0.60) | HTR6CXCR4CYP2D6KCNH2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | HTR6 2334/4885CXCR4 2/4885CYP2D6 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.